Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.

Chen EY, Blanke CD, Haller DG, Benson AB, Dragovich T, Lenz HJ, Robles C, Li H, Mori M, Mattek N, Sanborn RE, Lopez CD.

Am J Clin Oncol. 2018 May 18. doi: 10.1097/COC.0000000000000465. [Epub ahead of print]

PMID:
29782360
2.

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.

Giaccone G, Sanborn RE, Waqar SN, Martinez-Marti A, Ponce S, Zhen H, Kennealey G, Erickson-Viitanen S, Schaefer E.

Clin Lung Cancer. 2018 Mar 23. pii: S1525-7304(18)30058-5. doi: 10.1016/j.cllc.2018.03.016. [Epub ahead of print]

PMID:
29681434
3.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA.

Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.

PMID:
29563138
4.

A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.

Sanborn RE, Ross HJ, Aung S, Acheson A, Moudgil T, Puri S, Hilton T, Fisher B, Coffey T, Paustian C, Neuberger M, Walker E, Hu HM, Urba WJ, Fox BA.

J Immunother Cancer. 2017 Dec 19;5(1):103. doi: 10.1186/s40425-017-0306-6.

5.

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).

Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ.

Invest New Drugs. 2017 Oct;35(5):608-615. doi: 10.1007/s10637-017-0441-4. Epub 2017 Feb 16.

6.

A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.

Sanborn RE, Patel JD, Masters GA, Jayaram N, Stephens A, Guarino M, Misleh J, Wu J, Hanna N.

Cancer. 2017 Jan 1;123(2):303-311. doi: 10.1002/cncr.30287. Epub 2016 Sep 1.

7.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH.

J Clin Oncol. 2016 Sep 10;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761. Epub 2016 Jun 6.

8.

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA.

Lancet Oncol. 2016 Mar;17(3):299-308. doi: 10.1016/S1470-2045(15)00544-6. Epub 2016 Feb 6.

9.

Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.

Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Yang Y, Medeiros M, Zaknoen SL.

J Clin Oncol. 2015 Jan 10;33(2):189-94. doi: 10.1200/JCO.2014.55.5789. Epub 2014 Dec 1.

10.

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.

Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T.

Sci Transl Med. 2014 Apr 16;6(232):232ra51. doi: 10.1126/scitranslmed.3008068.

11.

Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma.

Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara DR.

Clin Lung Cancer. 2013 Jul;14(4):351-5. doi: 10.1016/j.cllc.2012.12.004. Epub 2013 Feb 14.

12.

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.

ClĂ©ment-DuchĂȘne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA.

Lung Cancer. 2012 Oct;78(1):57-62. doi: 10.1016/j.lungcan.2012.06.003. Epub 2012 Jul 17.

13.

Cisplatin versus carboplatin in NSCLC: is there one "best" answer?

Sanborn RE.

Curr Treat Options Oncol. 2008 Dec;9(4-6):326-42. doi: 10.1007/s11864-009-0085-5. Epub 2009 Feb 19. Review.

PMID:
19225891
14.

Erlotinib: applications in therapy and current status of research.

Sanborn RE, Davies AM.

Expert Rev Clin Pharmacol. 2009 Jan;2(1):15-36. doi: 10.1586/17512433.2.1.15.

PMID:
24422769
15.

Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement.

Sanborn RE, Lally BE.

Thorac Surg Clin. 2008 Nov;18(4):423-35. doi: 10.1016/j.thorsurg.2008.08.004. Review.

PMID:
19086611
16.

Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.

Tieu BH, Sanborn RE, Thomas CR Jr.

Thorac Surg Clin. 2008 Nov;18(4):403-15. doi: 10.1016/j.thorsurg.2008.07.004. Review.

PMID:
19086609
17.

Definitive chemoradiotherapy for non-small cell lung cancer with N2 disease.

Patel S, Sanborn RE, Thomas CR Jr.

Thorac Surg Clin. 2008 Nov;18(4):393-401. doi: 10.1016/j.thorsurg.2008.07.003. Review.

PMID:
19086608
18.

Cutaneous reactions to chemotherapy: commonly seen, less described, little understood.

Sanborn RE, Sauer DA.

Dermatol Clin. 2008 Jan;26(1):103-19, ix. Review.

PMID:
18023774
19.

The safety of bevacizumab.

Sanborn RE, Sandler AB.

Expert Opin Drug Saf. 2006 Mar;5(2):289-301. Review.

PMID:
16503749
20.

Gastrointestinal stromal tumors and the evolution of targeted therapy.

Sanborn RE, Blanke CD.

Clin Adv Hematol Oncol. 2005 Aug;3(8):647-57. Review.

PMID:
16167051
21.

What sanitation means to the processor.

SANBORN RE.

Food Ind. 1946 Jan;18:94-6. No abstract available.

PMID:
21009698

Supplemental Content

Loading ...
Support Center